The CDC panel's recommendation moves the U.S. closer to making the respiratory syncytial virus shots from Pfizer and GSK available to seniors.
which involves working with their healthcare provider to decide how much they will benefit from a shot.The panel's decision moves the U.S. one step closer to making jabs againstThe recommendation also comes weeks after the Food and Drug AdministrationThe virus is a common respiratory infection that usually causes mild, cold-like symptoms, but more severe cases in older adults and children.
Pfizer said that efficacy fell to 48.9% at "mid-season two" for less severe forms of the disease in that age group, down from about 66%.against severe RSV disease after two seasons, compared with 94% after one season, the company said Wednesday. Severe disease refers to cases that prevent normal, daily activities.Dr.
Melgar said adults ages 75 and older and those with an underlying medical condition are underrepresented in the phase three clinical trials from both companies. Seniors with a weak immune system were excluded from the trials altogether, he said.It's still unclear how much the shots will cost. GSK said it will price its vaccine between $200 and $295. Pfizer said it will price its shot between $180 to $270.The shots would help the U.S.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Pfizer RSV vaccine for older adults is only slightly less effective after 18 monthsPfizer will present the RSV vaccine results to a CDC advisory committee, which will decide when and how often the shot should be administered in the U.S.
Weiterlesen »
Next Vaccine You Should Get? Health Advisers May Recommend RSV ShotsGSK and Pfizer RSV vaccines were approved earlier this year by the FDA for adults aged 60 and older.
Weiterlesen »
CDC to investigate swine flu virus behind woman's death in BrazilThe CDC plans to probe samples collected from a fatal influenza infection in Brazil, after investigators discovered the death was caused by an H1N1 variant spreading in pigs.
Weiterlesen »
Outgoing CDC director says resignation spurred by sense of accomplishment and exhaustionThe outgoing head of the Centers for Disease Control and Prevention said her reasons for stepping down were complicated, driven in part by a desire to take a break from the frenetic pace of the job during a pandemic
Weiterlesen »
Outgoing CDC director says resignation spurred by sense of accomplishment and exhaustionThe outgoing head of the Centers for Disease Control and Prevention said her reasons for stepping down were complicated, driven in part by a desire to take a break from the frenetic pace of the job during a pandemic. Dr. Rochelle Walensky surprised many in public health circles last month by announcing her departure after just two years and five months. In an interview with the Associated Press, Walensky said she decided to step down because she felt she had shepherded the agency through the pandemic and needed a break from the intense schedule she’s kept the last few years.
Weiterlesen »
Outgoing CDC director says resignation spurred by sense of accomplishment and exhaustionThe outgoing head of the Centers for Disease Control and Prevention said her reasons for stepping down were complicated, driven in part by a desire to take a break from the frenetic pace of the job during a pandemic.
Weiterlesen »